✦ LIBER ✦

Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme

✍ Scribed by Christopher D. Turner; Susan Chi; Karen J. Marcus; Tobey MacDonald; Roger J. Packer; Tina Young Poussaint; Sridhar Vajapeyam; Nicole Ullrich; Liliana C. Goumnerova; R. Michael Scott; Caitlin Briody; Christine Chordas; Mary Ann Zimmerman; Mark W. Kieran

Publisher: Springer US
Year: 2006
Tongue: English
Weight: 199 KB
Volume: 82
Category: Article
ISSN: 0167-594X
DOI: 10.1007/s11060-006-9251-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of erlotinib with temozol

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

✍ David M. Peereboom; Dale R. Shepard; Manmeet S. Ahluwalia; Cathy J. Brewer; Neer 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 180 KB

Treatment of children with newly diagnos

Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant β-interferon and hyperfractionated radiation therapy: A Childrens Cancer Group phase I/II study

✍ Roger J. Packer; Michael Prados; Peter Phillips; H. Stacy Nicholson; James M. Bo 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 721 KB

## BACKGROUND. Prognosis for the majority of children with brain stem gliomas is dismal. In previous studies, recombinant beta-interferon (@IF) has been shown to be effective for children with recurrent brain stem gliomas and may also act synergistically with radiotherapy (RT). ## METHODS. Thir

Phase II study of temozolomide without r

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population

✍ Carol Alliot 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 1 views

Phase II study of temozolomide without r

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations

✍ Olivier-L. Chinot; Maryline Barrie; Elisabeth Frauger; Henry Dufour; Dominique F 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND Currently, the survival of patients age > 70 years with glioblastoma multiforme (GBM) ranges from 4 months to 6 months, although radiotherapy and/or chemotherapy may prolong survival in certain subgroups. Temozolomide is an oral chemotherapeutic agent with efficacy agains

Carboplatin and etoposide with hyperfrac

Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: A phase I/II study

✍ Walter, Andrew W.; Gajjar, Amar; Ochs, Judith S.; Langston, James W.; Sanford, R 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

## Background: Diffuse pontine gliomas remain one of the most lethal of pediatric malignancies despite the use of increasingly intensive therapies. we delivered intensive chemotherapy during and following 70.2 gy of hyperfractionated radiation therapy in an attempt to improve survival. ## Procedur

A Phase I study of concurrent RMP-7 and

A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas

✍ Roger J. Packer; Mark Krailo; Minesh Mehta; Katherine Warren; Jeffrey Allen; Reg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB

## Abstract ## BACKGROUND Ninety percent of children with diffuse, intrinsic brainstem tumors will die within 18 months of diagnosis. Radiotherapy is of transient benefit to these children, and a potential way to improve its efficacy is to add radiosensitizers. Carboplatin is antineoplastic and ra